The Experts below are selected from a list of 38631 Experts worldwide ranked by ideXlab platform
Xu K - One of the best experts on this subject based on the ideXlab platform.
-
Endovascular Stent Implantation for the treatment of subclavian steal syndrome
Journal of Interventional Radiology, 2012Co-Authors: Xu KAbstract:Objective To discuss the application of intravascular Stent Implantation in the treatment of subclavian steal syndrome.Methods Endovascular Stent Implantation was performed in thirteen patients with subclavian steal syndrome caused by severe stenosis of the proximal segment of subclavian artery(n = 7) or by arterial occlusive lesions(n = 6).Results Self-expandable Stent placement was successfully performed in all 13 patients.The pulse of the radial artery and the brachial artery returned to normal after the treatment.The retrograde blood flow in vertebral arteries disappeared and the subclavian steal phenomenon vanished.The retrograde brachial arteries puncture was employed in 4 patients with complete occlusion of subclavian artery.Conclusion For subclavian steal syndrome,endovascular Stent Implantation is a safe,effective and minimally-invasive therapeutic method.
Iassen Michev - One of the best experts on this subject based on the ideXlab platform.
-
Late restenosis following sirolimus-eluting Stent Implantation.
The American journal of cardiology, 2007Co-Authors: John Cosgrave, Simon Corbett, Gloria Melzi, Rade Babic, Giuseppe Biondi-zoccai, Flavio Airoldi, Alaide Chieffo, Giuseppe Sangiorgi, Matteo Montorfano, Iassen MichevAbstract:Despite encouraging results from randomized trials, concerns exist about long-term results of sirolimus-eluting Stent Implantation. We sought to determine whether in-Stent restenosis occurring >1 year ("late") after sirolimus-eluting Stent Implantation is a real clinical entity. We analyzed data on all sirolimus-eluting Stents implanted in our institution before March 2003. During the study period 928 lesions in 433 patients were treated. Angiographic follow-up was performed in 306 patients (70.6%) with 679 lesions (73.2%). Angiography after 1 year was performed only in symptomatic patients. We considered restenosis "early" if it occurred during the first year and late if after 1 year. Late restenosis required demonstration of a widely patent Stent at 6 to 9 months, with repeat angiography after 1 year demonstrating restenosis. Restenosis occurred in 160 lesions overall (23.5%). Of the 31 (4.6%) that were documented after 1 year, 13 were excluded from analysis due to absence of 6- to 9-month angiography; the remaining 18 (2.6%, 1.7 to 4.2) fulfilled our criteria for late restenosis (median time of documentation 607 days, interquartile range 511 to 923). In conclusion, late restenosis is an infrequent but real entity; its existence implies we should not discount the possibility of restenosis as the cause of symptoms that develop >1 year after sirolimus-eluting Stent Implantation.
Taiichiro Meguro - One of the best experts on this subject based on the ideXlab platform.
-
antiplatelet therapy and Stent thrombosis after sirolimus eluting Stent Implantation
Circulation, 2009Co-Authors: Takeshi Kimura, Toshihiro Tamura, Hitoshi Yasumoto, Yoshikazu Hiasa, Toshiya Muramatsu, Kazushige Kadota, Takeshi Morimoto, Yoshihisa Nakagawa, Hideo Nishikawa, Taiichiro MeguroAbstract:Background— The influences of antiplatelet therapy discontinuation on the risk of Stent thrombosis and long-term clinical outcomes after drug-eluting Stent Implantation have not yet been addressed adequately. Methods and Results— In an observational study in Japan, 2-year outcomes were assessed in 10 778 patients undergoing sirolimus-eluting Stent Implantation. Data on status of antiplatelet therapy during follow-up were collected prospectively. Incidences of definite Stent thrombosis were 0.34% at 30 days, 0.54% at 1 year, and 0.77% at 2 years. Thienopyridine use was maintained in 97%, 62%, and 50% of patients at 30 days, 1 year, and 2 years, respectively. Patients who discontinued both thienopyridine and aspirin had a significantly higher rate of Stent thrombosis than those who continued both in the intervals of 31 to 180 days, 181 to 365 days, and 366 to 548 days after Stent Implantation (1.76% versus 0.1%, P<0.001; 0.72% versus 0.07%, P=0.02; and 2.1% versus 0.14%, P=0.004, respectively). When discont...
Georg Lutter - One of the best experts on this subject based on the ideXlab platform.
-
Mitral valved Stent Implantation.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2010Co-Authors: Georg Lutter, René Quaden, Jochen Cremer, Kenji Iino, A Hagemann, Jochen Renner, Tim Hümme, Lucian LozonschiAbstract:Objective: To date, transfemoral and trans-apical valved Stent Implantation techniques are limited to the replacement of pulmonary and aortic valves in a strictly selected group of patients. The current study was designed to assess the short-term follow-up using a mitral valved Stent in off-pump technique. Methods: A self-expanding, repositionable mitral valved Stent was created for trans-apical Implantation. Five pigs underwent successful trans-catheter Implantation. Data were gathered to assess the animals’ haemodynamical stability after Stent Implantation (n = 5),6 h(n = 5)and1week(n = 4).ThevalvedStentfunctionwasassessedbytrans-oesophagealechocardiographyandventriculogram.Cardiac computed tomography (CT) was used to evaluate positioning of the new implant. Results: Precise valved Stent deployment and accurate subsequent adjustment of its intra-annular position allowed for reduction of paravalvular leakage in all animals. The deployment time ranged from 122 to 271 s and blood loss from 65 to 245 cc. Accurate positioning was established in all but one animal. The average mean transvalvular gradient and mean gradient across left ventricular outflow tract (LVOT) recorded immediately after deployment, 6 h and 1 week were 1.9 0.9 mmHg, 3.5 1.6 mmHg, 4.1 02.3 mmHg and 1.4 01.3 mmHg, 1.5 0.7 mmHg 1.9 0.7 mmHg, respectively. Mild regurgitation waspresentaftervalvedStentdeploymentinoneoutoffiveanimalsafter1 h,oneoutoffiveanimalsat6 h,andtwooutoffouranimalsat1week. All animals exhibited normal haemodynamics after mitral valved Stent Implantation and maintained stability for the period of monitoring (6 h). One animal died of unrecognised imperfect valved Stent positioning after 1 day. In the subsequent animals, valved Stent migration, embolisation, systolic anterior movement or LVOT obstruction was not observed after 1 week follow-up. Conclusions: The new mitral valved Stent can be deployed in a reproducible manner to achieve reliable Stent stability, minimal gradients across the LVOTand adequate valved Stent function in short-term follow-up. # 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
-
Transapical mitral valved Stent Implantation.
The Annals of thoracic surgery, 2008Co-Authors: Lucian Lozonschi, René Quaden, Niloo M. Edwards, Jochen Cremer, Georg LutterAbstract:Transcatheter aortic and pulmonary valve replacement is currently being tested in human trials. Efforts to create a valved Stent to replace the atrioventricular valves have shown limited success. This is due to their their complex anatomy and function. A self-expanding valved Stent was created for transapical replacement of the atrioventricular valve. Ten pigs underwent transapical off-pump mitral valved Stent Implantation. Data were gathered to assess the animals' hemodynamic stability for 60 minutes after Implantation. The valved Stent function was assessed by transesophageal echocardiography (TEE) and contrast left ventriculogram. All animals exhibited normal hemodynamics immediately after mitral valved Stent Implantation and maintained stability for the entire period of monitoring. Accurate positioning of the valved Stent was established in all animals. Mild paravalvular regurgitation was found in three out of ten animals by TEE and in two animals during left ventriculogram. No left ventricular outflow tract obstruction was encountered. Transapical off-pump mitral valved Stent Implantation is feasible in an acute experimental setting. Long-term function of the new valved Stent remains to be established.
John Cosgrave - One of the best experts on this subject based on the ideXlab platform.
-
Late restenosis following sirolimus-eluting Stent Implantation.
The American journal of cardiology, 2007Co-Authors: John Cosgrave, Simon Corbett, Gloria Melzi, Rade Babic, Giuseppe Biondi-zoccai, Flavio Airoldi, Alaide Chieffo, Giuseppe Sangiorgi, Matteo Montorfano, Iassen MichevAbstract:Despite encouraging results from randomized trials, concerns exist about long-term results of sirolimus-eluting Stent Implantation. We sought to determine whether in-Stent restenosis occurring >1 year ("late") after sirolimus-eluting Stent Implantation is a real clinical entity. We analyzed data on all sirolimus-eluting Stents implanted in our institution before March 2003. During the study period 928 lesions in 433 patients were treated. Angiographic follow-up was performed in 306 patients (70.6%) with 679 lesions (73.2%). Angiography after 1 year was performed only in symptomatic patients. We considered restenosis "early" if it occurred during the first year and late if after 1 year. Late restenosis required demonstration of a widely patent Stent at 6 to 9 months, with repeat angiography after 1 year demonstrating restenosis. Restenosis occurred in 160 lesions overall (23.5%). Of the 31 (4.6%) that were documented after 1 year, 13 were excluded from analysis due to absence of 6- to 9-month angiography; the remaining 18 (2.6%, 1.7 to 4.2) fulfilled our criteria for late restenosis (median time of documentation 607 days, interquartile range 511 to 923). In conclusion, late restenosis is an infrequent but real entity; its existence implies we should not discount the possibility of restenosis as the cause of symptoms that develop >1 year after sirolimus-eluting Stent Implantation.